Business Of Biotech

E269 - Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.

Published: September 1, 2025

Duration: 1:04:36

We love to hear from our listeners. Send us a message.

On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents. 

Access this and h...